Cryoglobulinemic vasculitis: having giant steps; but there are still unanswered questions
Date
2020-06-20Author
Karadag, Omer
Duran, Emine
xmlui.mirage2.itemSummaryView.MetaData
Show full item recordAbstract
Cryoglobulinemic vasculitis (CryoVas) is a systemic
immune-complex vasculitis which can be a life-threatening
condition. In their article recently published by Internal and
Emergency Medicine, Vacchi C et al. reported the safety
and effectiveness of biosimilar of Rituximab CT-P10 in the
treatment of CryoVas [1]. For a better understanding of this
article, an overarching look to the historical picture of Cryo-
Vas and details of the usage of biosimilars will be helpful.
URI
https://doi.org/10.1007/s11739-020-02481-2https://link.springer.com/article/10.1007/s11739-020-02481-2
http://hdl.handle.net/11655/23575
xmlui.mirage2.itemSummaryView.Collections
xmlui.dri2xhtml.METS-1.0.item-citation
Karadag, O., Duran, E. Cryoglobulinemic vasculitis: having giant steps; but there are still unanswered questions. Intern Emerg Med 16, 33–35 (2021). https://doi.org/10.1007/s11739-020-02481-2The following license files are associated with this item: